Please ensure Javascript is enabled for purposes of website accessibility

Why bluebird bio Stock Jumped Today

By Keith Speights - Mar 29, 2021 at 3:50PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors reacted positively to a key FDA approval.

What happened

Shares of bluebird bio (BLUE -2.39%) were jumping 4% as of 3:30 p.m. EDT on Monday after rising as much as 10.8% earlier in the day. The gain came after Bluebird and its partner Bristol Myers Squibb (BMY 0.30%) announced on Friday that the U.S. Food and Drug Administration (FDA) approved Abecma (ide-cel) as a fifth-line treatment for multiple myeloma.

So what

FDA approval was expected for Abecma. However, it came later than Bluebird hoped it would. The FDA issued a Refusal to File letter on Bluebird and BMS' first regulatory submission for the cell therapy in May 2020. The partners quickly addressed the FDA's issues, though, and refiled in July.

Hands holding a white card with "FDA Approved" printed on it

Image source: Getty Images.

Normally, approval as a fifth-line treatment would mean the commercial opportunity for a drug is very limited. In multiple myeloma, though, most patients progress through multiple therapies. An initial therapy might work at first but later become less effective, resulting in the patient relapsing. Physicians then usually prescribe a therapy in a different drug class.

FDA approval of Abecma came with a boxed warning for several potential adverse reactions including cytokine release syndrome and neurologic toxicities. Because of these possible safety issues, the drug will be available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS).

Now what

Bluebird's FDA win for Abecma as a fifth-line treatment could bode well for the biotech stock in the future. The drug is currently being evaluated in a late-stage study as a third-line treatment for multiple myeloma and in phase 1 and phase 2 studies for earlier-line settings. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

bluebird bio, Inc. Stock Quote
bluebird bio, Inc.
$3.27 (-2.39%) $0.08
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$76.19 (0.30%) $0.23

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.